Profile

Since its inception in 2019, Phathom has been focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases to transform the treatment landscape and improve the lives of patients suffering from acid-related gastrointestinal (GI) disorders. As part of this mission, Phathom licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). In late 2023, Phathom received FDA approval for its novel gastroesophageal reflux disease (GERD) treatment, VOQUEZNA®, marking the first major innovation to the U.S. GERD market in over 30 years.

Phathom currently markets VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn in adults, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. In addition, the company is also advancing its development program across multiple acid-related GI disorders, including As Needed dosing for Non-Erosive GERD (NERD) and Eosinophilic Esophagitis (EoE).

Visit Phathompharma.com 

Key Products

• VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, and for the healing and maintenance of healing of Erosive GERD in adults and associated heartburn in adults.


• VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.


• VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults.

Phathom is advancing its development program across multiple acid-related GI disorders, including Non-Erosive GERD and Eosinophilic Esophagitis (EoE). For more information, view their pipeline here.

Key Executives

Terrie Curran, President & Chief Executive Officer

Terrie Curran has served as Phathom’s President and Chief Executive Officer since 2019. She is the former President, Global Inflammation and Immunology (I&I) Franchise and member of the Executive Committee at Celgene Corporation and has more than 20 years of experience in the biopharmaceutical industry. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA®. Prior to joining Celgene, she served as Senior Vice President and General Manager, Global Women’s Health at Merck & Co. She currently serves on the Board of Arcutis Biotherapeutics (Nasdaq:ARQT), and previously served on the Board of Myovant Sciences and H. Lundbeck A/S. Ms. Curran holds graduate and bachelor’s degrees from the University of Technology Sydney.

Azmi Nabulsi, M.D., M.P.H., Chief Operating Officer

Azmi Nabulsi is Phathom’s Chief Operating Officer and a Co-Founder of the company. He is the former Deputy Chief Medical Officer, Chief Scientific Officer and Head of Global Development at Takeda Pharmaceuticals. In these roles, he led all global research and development, medical, regulatory, operations, and data analytics functions. In addition, he led research and development portfolio management strategy and planning, focusing on enhancing the company’s pipeline and productivity. Dr. Nabulsi has led or directed partnerships and alliances in gastroenterology, oncology, immunology, cardiovascular medicine, and metabolism. Prior to Takeda, he held leadership positions at Abbott Laboratories, including Head of Immunology and Oncology Ventures. He previously served on the Board of Directors for ReAlta Life Sciences, Inc. from 2020-2023. Dr. Nabulsi has an M.D. from Ain-Shams University in Cairo and an M.P.H. from the University of Minnesota.

Martin Gilligan, Chief Commercial Officer

Martin Gilligan is Phathom’s Chief Commercial Officer. He was the former Corporate Vice President in the Inflammation and Immunology Franchise at Celgene Corporation, where he led marketing, market access and business development. Mr. Gilligan held key leadership roles in the launch and growth of OTEZLA® through its sale to Amgen for $13.4B. Prior to joining Celgene, he has held both global and US sales and marketing roles, spanning 25 years in the biopharmaceutical industry. Mr. Gilligan holds a bachelor’s degree from Providence College and an M.B.A. from Rutgers University.

Molly Henderson, Chief Financial & Business Officer

Molly Henderson is Phathom’s Chief Financial and Business Officer and the former Chief Financial Officer of UroGen Pharma, a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She has over 20 years of extensive experience in the pharmaceutical industry.

Previously, Ms. Henderson served as Chief Financial Officer and Executive Vice President of Advaxis, Inc., Chief Financial Officer of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.), and prior to then, the Chief Business and Financial Officer and Senior Vice President of VirtualScopics, Inc. Additionally, she served as a member of the Board of Directors and Chair of the Audit Committee of Calliditas Therapeutics AB.

Ms. Henderson earned her MBA and MS in Accounting from the State University of New York at Buffalo.

Tom Harris, Chief Development Sciences Officer

Tom Harris serves as Phathom’s Chief Development Sciences Officer and is the former Senior Vice President and Head of Global Regulatory Affairs at Takeda, where he was responsible for all global regulatory matters at Takeda while overseeing regulatory personnel in US, Europe, Japan and Singapore from 2012 to 2019.

Previously, Mr. Harris held multiple positions of increasing responsibility over 19 years within Abbott International’s Global Regulatory Affairs function. He held the position as the Global Regulatory Head for the Abbott Immunology franchise, which included oversight and responsibility of the worldwide submissions of HUMIRA® for rheumatology, gastroenterology and dermatology indications. He also served as the Global Project Head leading Humira Global Project Teams in dermatology and new indications in spondyloarthropathies and uveitis. Before joining industry, Mr. Harris was a staff pharmacist at Good Shepherd Hospital in Barrington, IL.

Mr. Harris earned a B.S. in Pharmacy from the University of Iowa College of Pharmacy.

Eckhard Leifke, M.D., Chief Medical Officer

Dr. Leifke is Phathom’s Chief Medical Officer and the former Chief Medical Officer at Omeros. Prior to Omeros, he held executive roles at Sanofi, including Global Head/Vice President of Early Project & External Opportunities – Cardiovascular and Metabolism and Global Head/Vice President of Late-Stage Development – Diabetes.

Dr. Leifke has built global teams at pharmaceutical companies including Bayer and Takeda and led the global development of multiple early- and late-stage small molecule and biologic drug candidates to successful marketing authorizations worldwide.

Dr. Leifke holds an M.D. from the University of Freiburg, Germany and is board-certified in internal medicine and endocrinology.

Paul Cocja, Chief People Officer

Paul Cocja is Phathom’s Chief People Officer and the former Vice President, People and Organization for Novartis’ U.S. Pharmaceutical Division and most recently led their U.S. Transformation Office. He has over 35 years of Human Resources (HR) experience, the majority of which has been in the biopharmaceutical industry. Prior to his time at Novartis, Mr. Cocja served as Vice President, Human Resources at Celgene Corporation, leading HR teams supporting multiple global divisions.

In addition to leading many HR organizations in the U.S. and globally, Mr. Cocja has developed significant expertise in leadership development, organizational effectiveness and culture optimization.

Mr. Cocja holds a master’s degree in education with a concentration in adult learning theory from Seton Hall University and a bachelor’s degree in psychology from Drew University.

To learn more about Phathom’s management team, visit here.

Investors

Phathom went public in October 2019 and is listed on the Nasdaq Global Select Market under the trading symbol “PHAT.”

Phathom’s stock is covered by eight analyst institutions, including Goldman Sachs, Guggenheim, H.C. Wainwright, Jefferies, Needham & Company, Stifel, Craig-Hallum, and EVERCORE ISI.

For more information on Phathom’s stock and investor relations, visit here.

Corporate Responsibility

Phathom’s commitment to its employees, community, and the environment is integral to its mission. Through innovative programs, strategic partnerships, and the dedication of its team members, the company aims to create a lasting, positive impact on the world.

Employees

Phathom fosters a culture where employees are considered part of the “Phamily.” The team is composed of highly driven pharmaceutical professionals passionate about improving the lives of individuals suffering from gastrointestinal (GI) disorders. Collaboration is highly valued, both within the organization and with external partners, to leverage expertise and achieve shared goals. The company promotes a nimble, entrepreneurial environment emphasizing collective ownership, accountability, and achievement—key elements of its success. Employees benefit from competitive compensation, extensive benefit programs, and initiatives that prioritize their overall well-being and that of their families. Phathom’s equity programs and benefits reflect its “stake in the result” philosophy, rewarding employees when value is created for shareholders.

Diversity, Equity & Inclusion

Phathom prioritizes a diverse and inclusive culture, recognizing it as essential to the company’s success. This commitment is embedded in its policies, practices, and values. The company embraces individuals from diverse backgrounds, cultures, identities, and perspectives, ensuring all voices are heard and holding itself accountable to be equitable and just. By authentically supporting the people and communities impacted by its work, Phathom fosters a sense of inclusion and belonging.

Community

Phathom is dedicated to building strong relationships with the communities surrounding its New Jersey and Illinois offices. The company sponsors local events and encourages employees to participate in volunteer activities that strengthen these connections. Through its Corporate Giving Match program, Phathom amplifies the impact of employee donations by providing an annual matching contribution. Aligned with its focus on gastrointestinal health, Phathom actively supports events and initiatives in collaboration with GI advocacy partners. These efforts highlight the company’s dedication to advancing research, education, and awareness in the GI field.